#USA #New York #The Gross Law Firm #ESSA Pharma #EPIX

Important Notice for ESSA Pharma Inc. Shareholders

As we move through 2025, shareholders of ESSA Pharma Inc. (NASDAQ: EPIX) should be keenly aware of a crucial announcement from The Gross Law Firm, particularly those who purchased shares during the specified period. This notice, issued on February 24, 2025, serves as a reminder for shareholders to act promptly in order to claim their rights.

Key Details About Your Rights

If you purchased shares of EPIX between December 12, 2023, and October 31, 2024, it is essential to understand your potential involvement in a securities class action. The Gross Law Firm emphasizes that contacting them before the approaching deadline of March 25, 2025, is imperative if you wish to discuss your rights and any applicable class action claims.

Nature of the Allegations

The claims center around allegations that the company, during the defined class period, may have issued materially false or misleading statements regarding the efficacy of masofaniten combined with enzalutamide for prostate cancer treatment. Specifically, the complaint suggests that:
1. The combination did not demonstrate any clear efficacy advantage over enzalutamide alone.
2. Masofaniten’s effectiveness in treating prostate cancer was likely overstated.
3. A key study regarding this combination treatment was unlikely to meet its primary therapeutic endpoint, undermining prior assurances made to shareholders.
4. As a result, investors may have been misled during key communications from the company.

Steps for Shareholders

To ensure participation in this potentially critical legal action, shareholders must register their information, which can be done easily via The Gross Law Firm's dedicated web platform. Once registered, participants will gain access to ongoing updates through a portfolio monitoring system, keeping them informed throughout the lawsuit's lifecycle.

Why Act Now?

The necessity to act cannot be overstated. Failure to register by the official deadline could mean forfeiting the opportunity to be included in recovery efforts should the case be successful. Importantly, appointing a lead plaintiff is not a prerequisite for participation; all shareholders fitting the criteria have the right to engage with the class action.

About The Gross Law Firm

The Gross Law Firm is known for its advocacy on behalf of shareholders. They aim to ensure that investors who have faced losses because of corporate misconduct receive the justice they deserve. Their commitment is rooted in holding companies accountable for their actions and restoring investor confidence where possible.

For any shareholder of ESSA Pharma Inc., this moment is critical. Engaging with The Gross Law Firm might provide the avenue to protect your investments and potentially recover losses incurred due to misleading information from the company.

For assistance, shareholders are encouraged to reach out to The Gross Law Firm at their New York office, or via the official contact methods outlined in the original release. Don't wait—register today to secure your rights and join this important class action.

Conclusion

As the deadline approaches, the obligation to inform all shareholders about their rights becomes urgent. Don’t miss out on your chance to make your voice heard in the quest for justice and accountability within ESSA Pharma Inc.